Association of PDCD1 with susceptibility to systemic lupus erythematosus
Evidence of population-specific effects
Article first published online: 5 AUG 2004
Copyright © 2004 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 50, Issue 8, pages 2590–2597, August 2004
How to Cite
Ferreiros-Vidal, I., Gomez-Reino, J. J., Barros, F., Carracedo, A., Carreira, P., Gonzalez-Escribano, F., Liz, M., Martin, J., Ordi, J., Vicario, J. L. and Gonzalez, A. (2004), Association of PDCD1 with susceptibility to systemic lupus erythematosus. Arthritis & Rheumatism, 50: 2590–2597. doi: 10.1002/art.20436
- Issue published online: 5 AUG 2004
- Article first published online: 5 AUG 2004
- Manuscript Accepted: 13 APR 2004
- Manuscript Received: 2 JUL 2003
- Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III (Madrid, Spain). Grant Numbers: 01/3138, 02/0713
- DXID (Xunta de Galicia)
The A allele of the PD1.3 single-nucleotide polymorphism (SNP) on the programmed cell death gene PDCD1 was markedly more frequent in patients with systemic lupus erythematosus (SLE) than in unaffected controls in a recent study involving large sets of Swedish, European American, and Mexican families. This study sought to determine the role of PDCD1 in susceptibility to SLE in the Spanish population.
Seven PDCD1 SNPs were studied in 518 SLE patients and 800 healthy control subjects who had been recruited in 5 distant towns spanning continental Spain. Patients and controls were of Spanish ancestry. The diagnosis of SLE was in accordance with the American College of Rheumatology updated classification criteria.
The A allele of the PD1.3 polymorphism was significantly less frequent in Spanish female patients with SLE than in Spanish female controls (9.0% versus 13.0%, odds ratio 0.67, 95% confidence interval 0.50–0.89). This difference was consistent across the 5 sets of samples grouped by town of recruitment. The other PDCD1 SNPs were not associated with SLE susceptibility. The haplotype structure of PDCD1 in the Spanish controls was different from that reported in other healthy control populations.
Our results confirm the association of PDCD1 with susceptibility to SLE, but the findings show a lack of involvement of the PD1.3 SNP, which is contrary to the role of the PD1.3 A allele observed previously. These contradictory results probably reflect population differences in the haplotype structure of the PDCD1 locus. More research focusing on new polymorphisms and identifying associations in other populations will be needed to clarify the role of PDCD1 in SLE susceptibility.